Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2007
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study
Michael Herold, Antje Haas, Stefanie Srock, et al.
The Lancet. Oncology
|
February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Haematologica
|
October 30, 2025
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020
Linmiao Jiang, Marco Ladetto, Olivier Hermine, et al.
BMC Cancer
|
March 1, 2020
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08
Martin Fehr, Hanne Hawle, Stefanie Hayoz, et al.
Eclinicalmedicine
|
October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
Urban Novak, Martin Fehr, Sämi Schär, et al.
Blood Advances
|
August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Rudolf Benz, Kornelius Arn, Martin Andres, et al.
Blood Advances
|
May 10, 2022
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
Anastasios Stathis, Ulrich Mey, Sämi Schär, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 2025
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial
Justin Ferdinandus, Helen Kaul, Alexander Fosså, et al.
Swiss Medical Weekly
|
August 14, 2025
Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network
Max J Rieger, Andreas J Flammer, Sabine Gerull, et al.
Lancet (London, England)
|
May 5, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Martin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2007
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study
Michael Herold, Antje Haas, Stefanie Srock, et al.
The Lancet. Oncology
|
February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Haematologica
|
October 30, 2025
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020
Linmiao Jiang, Marco Ladetto, Olivier Hermine, et al.
BMC Cancer
|
March 1, 2020
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08
Martin Fehr, Hanne Hawle, Stefanie Hayoz, et al.
Eclinicalmedicine
|
October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
Urban Novak, Martin Fehr, Sämi Schär, et al.
Blood Advances
|
August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Rudolf Benz, Kornelius Arn, Martin Andres, et al.
Blood Advances
|
May 10, 2022
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
Anastasios Stathis, Ulrich Mey, Sämi Schär, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 2025
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial
Justin Ferdinandus, Helen Kaul, Alexander Fosså, et al.
Swiss Medical Weekly
|
August 14, 2025
Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network
Max J Rieger, Andreas J Flammer, Sabine Gerull, et al.
Lancet (London, England)
|
May 5, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Martin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
Page
of 6